These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 26567140)

  • 21. Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis.
    Kharbanda A; Walter DM; Gudiel AA; Schek N; Feldser DM; Witze ES
    Sci Signal; 2020 Mar; 13(621):. PubMed ID: 32127496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities.
    Kerr EM; Gaude E; Turrell FK; Frezza C; Martins CP
    Nature; 2016 Mar; 531(7592):110-3. PubMed ID: 26909577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mouse model of proximal colon-specific tumorigenesis driven by microsatellite instability-induced Cre-mediated inactivation of Apc and activation of Kras.
    Kawaguchi Y; Hinoi T; Saito Y; Adachi T; Miguchi M; Niitsu H; Sasada T; Shimomura M; Egi H; Oka S; Tanaka S; Chayama K; Sentani K; Oue N; Yasui W; Ohdan H
    J Gastroenterol; 2016 May; 51(5):447-57. PubMed ID: 26361962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of Mutant
    Zhou X; Padanad MS; Evers BM; Smith B; Novaresi N; Suresh S; Richardson JA; Stein E; Zhu J; Hammer RE; O'Donnell KA
    Mol Cancer Res; 2019 Feb; 17(2):594-603. PubMed ID: 30409919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.
    Chang YI; You X; Kong G; Ranheim EA; Wang J; Du J; Liu Y; Zhou Y; Ryu MJ; Zhang J
    Leukemia; 2015 Sep; 29(9):1847-56. PubMed ID: 25801914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endoplasmic reticulum chaperone GRP78/BiP is critical for mutant Kras-driven lung tumorigenesis.
    Rangel DF; Dubeau L; Park R; Chan P; Ha DP; Pulido MA; Mullen DJ; Vorobyova I; Zhou B; Borok Z; Offringa IA; Lee AS
    Oncogene; 2021 May; 40(20):3624-3632. PubMed ID: 33931739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting metabolic reprogramming in KRAS-driven cancers.
    Kawada K; Toda K; Sakai Y
    Int J Clin Oncol; 2017 Aug; 22(4):651-659. PubMed ID: 28647837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.
    Westcott PM; Halliwill KD; To MD; Rashid M; Rust AG; Keane TM; Delrosario R; Jen KY; Gurley KE; Kemp CJ; Fredlund E; Quigley DA; Adams DJ; Balmain A
    Nature; 2015 Jan; 517(7535):489-92. PubMed ID: 25363767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity.
    Liang MC; Ma J; Chen L; Kozlowski P; Qin W; Li D; Goto J; Shimamura T; Hayes DN; Meyerson M; Kwiatkowski DJ; Wong KK
    Oncogene; 2010 Mar; 29(11):1588-97. PubMed ID: 19966866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nitrilase 1 modulates lung tumor progression in vitro and in vivo.
    Wang YA; Sun Y; Le Blanc JM; Solomides C; Zhan T; Lu B
    Oncotarget; 2016 Apr; 7(16):21381-92. PubMed ID: 26967383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p53 dosage can impede KrasG12D- and KrasQ61R-mediated tumorigenesis.
    Le Roux Ö; Everitt JI; Counter CM
    PLoS One; 2024; 19(3):e0292189. PubMed ID: 38547169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Downregulation of Notch Signaling in Kras-Induced Gastric Metaplasia.
    Chung WC; Zhou Y; Atfi A; Xu K
    Neoplasia; 2019 Aug; 21(8):810-821. PubMed ID: 31276933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KRAS
    Zhou ZW; Ambrogio C; Bera AK; Li Q; Li XX; Li L; Son J; Gondi S; Li J; Campbell E; Jin H; Okoro JJ; Xu CX; Janne PA; Westover KD
    Cancer Res; 2020 Sep; 80(17):3719-3731. PubMed ID: 32605999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
    Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
    Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer.
    Miller P; Akama-Garren EH; Owen RP; Demetriou C; Carroll TM; Slee E; Al Moussawi K; Ellis M; Goldin R; O'Neill E; Lu X
    Cell Death Differ; 2023 Jul; 30(7):1619-1635. PubMed ID: 37270580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.
    Drosten M; Barbacid M
    J Mol Med (Berl); 2016 Feb; 94(2):121-35. PubMed ID: 26526121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations.
    Ludovini V; Bianconi F; Pistola L; Pistola V; Chiari R; Colella R; Bellezza G; Tofanetti FR; Siggillino A; Baldelli E; Flacco A; Giuffrida D; Sidoni A; Crinò L
    Cancer Chemother Pharmacol; 2012 May; 69(5):1289-99. PubMed ID: 22302407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.
    Ohm AM; Tan AC; Heasley LE; Reyland ME
    Oncogene; 2017 Jul; 36(30):4370-4378. PubMed ID: 28368426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.